Navigation Links
First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain
Date:1/14/2014

onjugate technology platform; and the potential of certain of our other drug candidates and those of our collaboration partners. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, observations and assumptions regarding the potential of our business, drug candidates, and our technology. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) the statements regarding the therapeutic potential of NKTR-171 are based on preclinical data only and data from clinical studies may not confirm these potential therapeutic benefits; (ii) NKTR-171 is in early stage clinical development and could fail at any time due to numerous unpredictable and significant risks related to safety, efficacy and other important findings that can negatively impact clinical development; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates such as NKTR-171 is therefore very uncertain and unpredictable and could unexpectedly fail at any time; (iv) patents may not issue from our patent applications for NKTR-171 or additional intellectual property licenses from third parties may be required; and (v) the outcome of any potential intellectual property or other litigation related to our proprietary drug candidates.  Other important risks and uncertainties are detailed in our
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information
2. 2014 Beauty Breakthrough -- Age-Defying Laser brings professional, anti-aging treatments into the home for the first time
3. QIAGEN and Exosome Diagnostics to Develop First-In-Class, Non-Invasive Diagnostics for Key Genetic Biomarkers in Lung and Other Cancers
4. Hill-Rom Holdings, Inc. Hosts Fiscal 2014 First Quarter Earnings Conference Call and Webcast
5. Xlumena Announces Initial Commercial Use of its First-in-Class AXIOS Stent and Delivery System for Treatment of Pancreatic Pseudocysts and Fluid Collections
6. Hologic to Release First Quarter Fiscal 2014 Operating Results on Monday, February 3, 2014
7. Philips receives FDA clearance for First-Ever Spectral Breast Density Measurement Application
8. Harrisburg-based Cardiovascular Institute Performs First MitraClip Procedure in Pennsylvania
9. Caris Life Sciences Receives Tumor Profiling Industrys First ISO 15189 Medical Laboratory Accreditation
10. According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients
11. Lilly Declares First-Quarter 2014 Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... BRUNSWICK, N.J. , May 7, 2015 ... a first-of-its-kind partnership that enlists a third party to ... Johnson & Johnson (Janssen) for compassionate use ... as a pilot program focused on a single Janssen ... that will be applicable more broadly across Johnson & ...
(Date:5/6/2015)... May 6, 2015  Zimmer Holdings, Inc. (NYSE and SIX: ... it will be presenting at the Bank of America Merrill ... in Las Vegas, Nevada on Wednesday, ... A live webcast of the presentation can be accessed via ... will be archived for replay following the conference. ...
(Date:5/6/2015)... 2015  The fairness of the proposed acquisition of ... Pharmaceuticals, Inc. ("Alexion") is being investigated by WeissLaw LLP, ... possible breaches of fiduciary duty and other violations of ... agreeing to sell the Company to Alexion.  On May ... Alexion to acquire GEVA in a transaction valued at ...
Breaking Medicine Technology:Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 2Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 3Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 4Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 5WeissLaw LLP Investigates the Synageva Biopharma Corp. Acquisition 2
... Dec. 9, 2011 /PRNewswire-iReach/ -- Novel Health ... the publication of  2010-2011 market trends study called ,What,s ... The published article is an analysis of sales, pricing, ... specialty biologic products. This study highlights several emerging trends ...
... FRAMINGHAM, Mass. and SYDNEY, Dec. 9, 2011 HeartWare ... HIN), a leading innovator of less invasive, miniaturized circulatory ... heart failure, today announced that CEO Doug Godshall is ... Conference at 10:50 a.m. EST on Wednesday, December 14, ...
Cached Medicine Technology:Biotech Market Trends Study Shows New Competitive Dynamics and Increasing Reimbursement Hurdles 2Biotech Market Trends Study Shows New Competitive Dynamics and Increasing Reimbursement Hurdles 3Biotech Market Trends Study Shows New Competitive Dynamics and Increasing Reimbursement Hurdles 4HeartWare to Present at the Oppenheimer 22nd Annual Healthcare Conference 2
(Date:5/7/2015)... May 07, 2015 Centurion Service ... is proud to announce the upcoming live auction to ... surgery centers and other medical facilities from around the ... including radiology, surgery, endoscopy, lab, anesthesia, infusion, exam and ... Tuesday, May 12 starting at 9:00am PDT. The equipment ...
(Date:5/7/2015)... May 07, 2015 More than most public ... With constant media attention personal issues become public affairs and ... SCI TV , industry expert Katharine Nohr ... profile athletes Justin Gatlin and Michael Phelps. , With a ... her to start her own company, Nohr Sports Risk Management. ...
(Date:5/7/2015)... Wisconsin (PRWEB) May 07, 2015 When people ... give more consideration to their roofs than their basements. However, ... for flooding in crawlspaces and basements. While flooding is an ... to keep crawlspaces and unfinished areas dry to avoid a ... of a Damp Basement, Even small amounts of water can ...
(Date:5/7/2015)... (PRWEB) May 07, 2015 Aureus Medical ... travel nursing jobs and a variety of ... has released an infographic spotlighting top theme parks ... is aimed at thrill-seeking mobile healthcare professionals who are ... Travel healthcare careers offer an opportunity for the travel ...
(Date:5/7/2015)... 07, 2015 Dynamic Path, a leader ... its new free Alcohol Safety Exam Prep module ... restaurant managers, professional bartenders, and any front-of-house staff who ... Certification. The material encompasses topics taught in the National ... students can take the ServSafe Alcohol Proctored Exam or ...
Breaking Medicine News(10 mins):Health News:Centurion to Sell Surplus Medical Equipment in Online and On-site Auction 2Health News:Katharine Nohr Discusses Risk Management in Sports on SCI TV 2Health News:Katharine Nohr Discusses Risk Management in Sports on SCI TV 3Health News:Spring Storms Bring Musty Smell Inside 2Health News:Spring Storms Bring Musty Smell Inside 3Health News:Get to Know the Top Theme Parks: Aureus Medical Releases Infographic for the Travel Nurse and Other Travel Healthcare Professionals 2Health News:Dynamic Path Adds Alcohol Safety Exam Prep Module to Test Preparation Offerings 2
... between ages 15 and 45. When a tumor is found, ... way it's removed, which often leaves men infertile, //can change ... all men who have testicular tumors in one testicle will ... they will have no hormonproduction and no possibility for fertility. ...
... fight another. Researchers say the little-known virus GBV-C, also ... a key to helping researchers devise new strategies against ... Multicenter Acquired Immunodeficiency Syndrome Cohort Study, in which investigators ... United States for more than 15 years. The study ...
... fluids may do more harm than good for patients ... previous studies to determine if recommending patients with respiratory ... shown during a respiratory infection, such as a cold ... specific hormone that conserves water. Thus, researchers say giving ...
... errors that occur in pediatric intensive care units are more ... more than 11,800 children who were admitted into pediatric intensive ... defined an error as any preventable event that may cause ... were reported during the course of the study. Nearly 70 ...
... can no longer be considered a benign condition or ... 60 percent of overweight children have at least one ... type 2 diabetes is increasing rapidly in developing countries ... 2 diabetes in developing countries has been attributed to ...
... or other painkillers that is characterized by the onset ... after taking the medications. British researchers analyzed more than ... percent of adults and about 5 percent of children ... these patients were also sensitive to over-the-counter non-steroidal anti-inflammatory ...
Cached Medicine News:Health News:Childhood Weight Gain Found To Increase The Risk of Diabetes 2
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
... optimize the accuracy and precision of Finnpipettes. ... widely recognized by customers throughout the world. ... the years and now covers a full ... filter tips, certified pure tips, stepper tips ...
MBP's 200 L large orifice tip is perfect for handling fragile cells, viscous samples and genomic....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
Medicine Products: